| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
The current research aimed on identifying the mechanism of transformation of low grade hematological malignancies into a highly aggressive tumor, and to develop novel therapeutics for these types of tumors through reprogramming technology. In order to understand the mechanism of transformation in hematological malignancies, we also focused on a rare subtype of lymphoma called plasmablastic lymphoma, and identified that the aberrant expression of Xbp1(s) led to the transformation into plasmablastic appearance, and that inhibition of Xbp1(s) through a proteasome inhibitor bortezomib harbored a potential for treatment for this type of lymphoma.
|
